Kardigan, Inc. Common Stock KARD
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:48:00.638Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:26:35.462504661Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T02:45:57.742132+00:00
Kardigan, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 10.72 | 586.3% | 47.3% | |||
| 25Δ | 11.97 | 501.7% | 39.3% | |||
| 30Δ | 13.22 | 417.1% | 31.3% | |||
| 35Δ | 14.47 | 332.5% | 23.4% | |||
| 40Δ | 15.28 | 280.6% | 18.3% | |||
| 45Δ | 15.76 | 252.9% | 15.5% | |||
| 50Δ | 16.07 | 72.8% | 6.9% | 16.24 | 225.3% | 12.7% |
| 55Δ | 15.80 | 70.1% | 5.7% | 16.73 | 197.6% | 9.8% |
| 60Δ | 15.53 | 67.4% | 4.4% | 17.21 | 169.9% | 7.0% |
| 65Δ | 15.26 | 64.7% | 3.2% | 17.66 | 149.5% | 5.0% |
| 70Δ | 18.06 | 139.8% | 4.2% | |||
| 75Δ | 18.45 | 130.1% | 3.4% | |||
| 80Δ | 18.85 | 120.4% | 2.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.72
- IV
- 586.3%
- B/E move
- 47.3%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.97
- IV
- 501.7%
- B/E move
- 39.3%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.22
- IV
- 417.1%
- B/E move
- 31.3%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.47
- IV
- 332.5%
- B/E move
- 23.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.28
- IV
- 280.6%
- B/E move
- 18.3%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.76
- IV
- 252.9%
- B/E move
- 15.5%
50Δ
- Pseudo strike
- 16.07
- IV
- 72.8%
- B/E move
- 6.9%
- Pseudo strike
- 16.24
- IV
- 225.3%
- B/E move
- 12.7%
55Δ
- Pseudo strike
- 15.80
- IV
- 70.1%
- B/E move
- 5.7%
- Pseudo strike
- 16.73
- IV
- 197.6%
- B/E move
- 9.8%
60Δ
- Pseudo strike
- 15.53
- IV
- 67.4%
- B/E move
- 4.4%
- Pseudo strike
- 17.21
- IV
- 169.9%
- B/E move
- 7.0%
65Δ
- Pseudo strike
- 15.26
- IV
- 64.7%
- B/E move
- 3.2%
- Pseudo strike
- 17.66
- IV
- 149.5%
- B/E move
- 5.0%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.06
- IV
- 139.8%
- B/E move
- 4.2%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.45
- IV
- 130.1%
- B/E move
- 3.4%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.85
- IV
- 120.4%
- B/E move
- 2.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 79.91% | |
| 79.43% | |
| 100.85% | |
| 82.45% | |
| 82.13% | |
| 101.43% | |
| 109.66% | |
| 108.06% | |
| 81.28% | |
| 82.51% |
Biotechnology
KLRA
Kailera Therapeutics, Inc. is a cutting-edge biotechnology company dedicated to developing innovative gene therapies for rare genetic diseases, addressing critical unmet medical…
More →KOD
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States…
More →KPTI
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and…
More →KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from…
More →KRRO
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent…
More →KRYS
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company…
More →